IDH1 and cholangiocarcinoma: In particular, in IDH1-mutated CCA patients’ refractories to previous systemic therapies, ivosidenib (AG120) showed a significant—albeit small—improvement in the median PFS versus the placebo (2.7 months versus 1.4 months; HR: 0.37; 95% CI: 0.25–0.54; p = 0.001) and a DCR of 53.2% (3 RP and 63 SD out of 124 patients).